Kavar Capital Partners LLC Boosts Stake in Gilead Sciences, Inc. (GILD)

Kavar Capital Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 39,230 shares of the biopharmaceutical company’s stock after purchasing an additional 1,350 shares during the quarter. Gilead Sciences accounts for about 1.1% of Kavar Capital Partners LLC’s investment portfolio, making the stock its 29th biggest position. Kavar Capital Partners LLC’s holdings in Gilead Sciences were worth $2,550,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. FTB Advisors Inc. increased its holdings in shares of Gilead Sciences by 97.3% during the 1st quarter. FTB Advisors Inc. now owns 137,223 shares of the biopharmaceutical company’s stock worth $8,920,000 after purchasing an additional 67,686 shares during the period. Arrow Financial Corp increased its holdings in shares of Gilead Sciences by 2.7% during the 1st quarter. Arrow Financial Corp now owns 7,949 shares of the biopharmaceutical company’s stock worth $517,000 after purchasing an additional 210 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. Daiwa Securities Group Inc. now owns 65,634 shares of the biopharmaceutical company’s stock worth $4,267,000 after purchasing an additional 529 shares during the period. World Asset Management Inc increased its holdings in shares of Gilead Sciences by 12.9% during the 1st quarter. World Asset Management Inc now owns 100,218 shares of the biopharmaceutical company’s stock worth $6,515,000 after purchasing an additional 11,484 shares during the period. Finally, Inlet Private Wealth LLC increased its stake in Gilead Sciences by 27.8% in the first quarter. Inlet Private Wealth LLC now owns 6,900 shares of the biopharmaceutical company’s stock valued at $449,000 after acquiring an additional 1,500 shares during the period. Institutional investors own 80.27% of the company’s stock.

Shares of Gilead Sciences stock opened at $67.13 on Friday. The company has a current ratio of 3.38, a quick ratio of 3.30 and a debt-to-equity ratio of 1.19. The stock has a market cap of $85.58 billion, a price-to-earnings ratio of 10.39, a PEG ratio of 0.89 and a beta of 1.14. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The firm had revenue of $5.28 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 earnings per share. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 6.2 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 3.75%. Gilead Sciences’s dividend payout ratio is 40.98%.

A number of analysts recently weighed in on GILD shares. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, April 22nd. Wells Fargo & Co cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $95.00 to $68.00 in a research note on Monday, February 11th. Citigroup reissued a “buy” rating and issued a $100.00 target price on shares of Gilead Sciences in a research note on Tuesday, February 5th. Oppenheimer set a $85.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, April 22nd. Finally, ValuEngine cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $81.47.

In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the sale, the director now directly owns 57,560 shares of the company’s stock, valued at $3,745,429.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the sale, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Insiders have sold 47,670 shares of company stock worth $3,142,526 over the last ninety days. Insiders own 0.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/05/kavar-capital-partners-llc-boosts-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.